CRISPR Therapeutics AG (CRSP) Retained Earnings (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Retained Earnings data on file, last reported at -$2.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 37.85% year-over-year to -$2.1 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.1 billion (down 37.85% YoY), and the FY2025 full-year result was -$1.9 billion, down 42.58% from the prior year.
• Retained Earnings eased to -$2.1 billion in Q1 2026, from -$1.9 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.9 million in Q4 2023 to a low of -$2.1 billion in Q1 2026.
• A 5-year average of -$916.8 million and a median of -$1.1 billion in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings tumbled 95421.43% in 2022 and surged 100.23% in 2023, its largest moves.
• Tracing CRSP's Retained Earnings over 5 years: stood at -$846.1 million in 2022, then surged by 100.23% to $1.9 million in 2023, then sank by 71503.66% to -$1.4 billion in 2024, then sank by 42.58% to -$1.9 billion in 2025, then fell by 6.31% to -$2.1 billion in 2026.
• Business Quant data shows CRSP's Retained Earnings at -$2.1 billion in Q1 2026, -$1.9 billion in Q4 2025, and -$1.8 billion in Q3 2025.